U.S. BIOSCIENCE NAMES RUSSELL MCLAUCHLAN PRESIDENT
U.S. BIOSCIENCE NAMES RUSSELL MCLAUCHLAN PRESIDENT WEST CONSHOHOCKEN, Pa., April 27 /PRNewswire/ -- Russell C.
McLauchlan has been named president and chief operating officer of U.S. Bioscience Inc. (AMEX: UBS), a pharmaceutical company specializing in new treatments for cancer and related diseases. He will be responsible for the company's worldwide commercial activities including sales, marketing, business development and manufacturing. He will report to Philip S. Schein, M.D., chairman and chief executive officer, who had also held the title of president.
McLauchlan spent nearly 20 years with the American Cyanamid Co., most recently serving as vice president and general manager of Lederle Pharmaceuticals, where he had profit and loss responsibility for that operating unit. Earlier at Cyanamid he held a number of senior marketing and sales positions in the United States and abroad. For the three years prior to joining U.S. Bioscience, he was president and chief operating officer of Immunomedics Inc., where he directed the development and marketing of products to diagnose and treat cancer. Dr. Schein noted that McLauchlan's in-depth industry background "will be of immense value to U.S. Bioscience as we move closer to becoming an integrated pharmaceutical company. His experience in managing the development and marketing of products to treat cancer is particularly relevant to our company's business focus." Based in West Conshohocken, U.S. Bioscience is a pharmaceutical company specializing in the development and commercialization of products to increase the survival and quality of life of patients with cancer and allied diseases. The company's portfolio includes a broad spectrum of cancer drugs, including four products in the final stages of development. One compound, altretamine, is marketed under the name Hexalen(R) in the United States. -0- 4/27/92 /CONTACT: Robert I. Kriebel of U.S. Bioscience, 215-832-4503/ (UBS) CO: U.S. Bioscience ST: Pennsylvania IN: MTC SU: PER
MM-DG -- SJ001 -- 2919 04/27/92 08:03 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||Apr 27, 1992|
|Previous Article:||VIATECH PROJECTS FIRST QUARTER RESULTS AND ANNOUNCES STOCK BUYBACK|
|Next Article:||AT&T PARADYNE ANNOUNCES PRICE REDUCTION, NEW COST-EFFECTIVE MODEM AND ENHANCEMENTS FOR COMSPHERE SERIES|